Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:37 AM
Ignite Modification Date:
2025-12-26 @ 10:37 AM
NCT ID:
NCT00057928
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of primary carcinoma of the cervix, meeting 1 of the following staging criteria:
* Metastatic (stage IVB)
* Recurrent after prior complete response to primary treatment with surgery or radiotherapy
* Persistent after surgery or radiotherapy
* Measurable disease
PATIENT CHARACTERISTICS:
Age
* Not specified
Performance status
* Zubrod 0-1
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Creatinine less than upper limit of normal OR
* Creatinine clearance greater than 40 mL/min
Other
* Not pregnant or nursing
* Fertile patients must use effective contraception
* No grade 2 or greater sensory or motor neuropathy
* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* More than 6 months since prior single-agent chemotherapy as a radiosensitizer
Endocrine therapy
* Not specified
Radiotherapy
* See Disease Characteristics
* At least 28 days since prior radiotherapy
* No prior radiotherapy to measurable target lesions
* No concurrent palliative radiotherapy
Surgery
* See Disease Characteristics
* Recovered from prior surgery
Other
* No prior systemic therapy
* No other concurrent antitumor therapy
Healthy Volunteers:
False
Sex:
FEMALE
Study:
NCT00057928
Study Brief:
Protocol Section:
NCT00057928